TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 107 filers reported holding TARSUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,928,656 | -11.6% | 1,796,773 | -10.1% | 2.23% | -25.4% |
| Q2 2023 | $36,128,850 | +304.0% | 1,999,383 | +282.8% | 3.00% | +250.3% |
| Q3 2022 | $8,942,000 | +14.6% | 522,329 | -2.3% | 0.86% | +13.4% |
| Q2 2022 | $7,804,000 | -13.2% | 534,524 | 0.0% | 0.75% | -12.8% |
| Q1 2022 | $8,991,000 | -22.3% | 534,524 | +3.9% | 0.86% | -17.6% |
| Q4 2021 | $11,572,000 | +4.4% | 514,289 | 0.0% | 1.05% | +100.0% |
| Q3 2021 | $11,083,000 | -25.6% | 514,289 | 0.0% | 0.52% | -32.5% |
| Q2 2021 | $14,904,000 | – | 514,289 | – | 0.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,084,370 | $30,432,000 | 4.62% |
| Vivo Capital, LLC | 2,312,368 | $33,761,000 | 3.39% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $26,098,000 | 2.46% |
| Cormorant Asset Management, LP | 1,875,000 | $27,375,000 | 2.07% |
| Sands Capital Ventures, LLC | 260,000 | $3,796,000 | 1.04% |
| Ghost Tree Capital, LLC | 120,000 | $1,752,000 | 0.91% |
| RTW INVESTMENTS, LP | 2,013,601 | $29,399,000 | 0.76% |
| COWEN AND COMPANY, LLC | 534,524 | $7,804,000 | 0.75% |
| Perceptive Advisors | 1,296,416 | $18,927,000 | 0.59% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $19,334,000 | 0.40% |